Pharming GroupPHAR +0.53%76 Days Payable is 769.60 as of Mar. 2026, which is 334% above its 10-year median of 177.40. GuruFocus rates PHAR with a GF Score™ of 76/100 and a GF Value™ of $14.42 (Fairly Valued). The stock has 1 warning sign investors should review. Among 706 Biotechnology companies, Pharming Group ranks better than 80.74% on this metric.
The historical rank and industry rank for Pharming Group's Days Payable or its related term are showing as below:
PHAR'
s Days Payable Range Over the Past 10 Years
Min: 79.59 Med: 177.4 Max: 573.27
Current: 573.27
During the past 13 years, Pharming Group's highest Days Payable was 573.27. The lowest was 79.59. And the median was 177.40.
PHAR's Days Payable is ranked better than 80.74% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs PHAR: 573.27
Pharming Group's Days Payable
increased
from Mar. 2025 (432.25) to Mar. 2026 (769.60).
It may suggest that Pharming Groupdelayed paying its suppliers.
Pharming Group Days Payable Related Terms
Pharming Group Days Payable Historical Data
* Premium members only.
The historical data trend for Pharming Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharming Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharming Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharming Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a Days Payable of 769.60 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharming Group and its competitors. This is 334% above median its historical median of 177.40. Over the past decade, Pharming Group's Days Payable has ranged from 79.59 to 573.27. According to the industry distribution chart, Pharming Group ranks #136 out of 706 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Pharming Group's Days Payable too high?
Pharming Group's current Days Payable of 769.60 is 334% above median its 10-year median of 177.40. Over the past 10 years, this metric has ranged from a low of 79.59 to a high of 573.27. The Biotechnology industry median Days Payable is 113.56. Pharming Group's value of 769.60 is 577.7% above this industry median. Based on the distribution chart, Pharming Group ranks #136 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #136 out of 706 companies for Days Payable. This places Pharming Group in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Pharming Group's value of 769.60 is 577.7% above this benchmark. Historically, Pharming Group's own Days Payable has ranged from 79.59 to 573.27 over the past decade. While the company's 10-year median is 177.40 vs. the industry median of 113.56, Pharming Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Days Payable of 769.60 is 577.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Days Payable is 769.60, which is 334% above median its own 10-year median of 177.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.42, compared to a current price of $13.34 — trading 7.5% below its estimated fair value. The current Days Payable is 769.60, which is 334% above median its 10-year median of 177.40 and 577.7% above the Biotechnology industry median of 113.56. Pharming Group's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharming Group (PHAR), the current Days Payable is 769.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.34 is trading 7.5% below its estimated GF Value™ of $14.42.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Days Payable: 769.60 (334% above median its 10-year median of 177.40)
GF Value™: $14.42 vs. price of $13.34 (7.5% below fair value)
Industry Position: 577.7% above the Biotechnology median (#136 of 706)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score
Get the complete analysis for PHAR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
